0O9B.IL - Almirall, S.A.
Almirall, S.A.
Ronda Del General Miter, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 1,814
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Carlos Gallardo Piqué | CEO & Chairman | 50k | N/A | 1972 |
| Mr. Michael McClellan | Exec. VP of Fin., CFO & Member of Management Board | N/A | N/A | 1972 |
| Mr. Eloi Crespo Cervera | Sr. VP of Industrial Operations & Member of Management Board | N/A | N/A | N/A |
| Mr. Jordi Sabé Richer | Sr. VP of Corp. Devel. & Member of Management Board | N/A | N/A | N/A |
| Mr. Esteve Conesa Panicot | Sr. VP of HR & Member of Management Board | N/A | N/A | N/A |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board | N/A | N/A | N/A |
| Mr. Pablo Alvarez | Member of Management Board, Pres of Almirall US & GM of Almirall US | N/A | N/A | N/A |
| Dr. Karl Ziegelbauer | Exec. VP of R&D, CSO and Member of Management Board | N/A | N/A | N/A |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board | N/A | N/A | N/A |
| Ms. Isabel Gomes | Gen. Counsel & Member of Management Board | N/A | N/A | N/A |
Description
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Corporate governance
Almirall, S.A.’s ISS governance QualityScore as of 1 June 2023 is 4. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 2; Compensation: 6.
